{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:06:33Z","timestamp":1787504793491,"version":"build-2736575974"},"reference-count":126,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS36126"],"award-info":[{"award-number":["R01 NS36126"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["nd 2R01 NS034239"],"award-info":[{"award-number":["nd 2R01 NS034239"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroimmunity drives the pathophysiology of Parkinson\u2019s disease (PD). This disease affects both the central and peripheral nervous systems. The immune system is engaged through the progressive accumulation of alpha-synuclein (\u03b1-syn), a driver of immunity and a pathological hallmark of PD. Consequent \u03b1-syn-induced immune activation leads to neuronal damage. This leads not only to the activation of microglia within the central nervous system, but also to the recruitment and activation of peripheral immune cells that infiltrate the brain and contribute to a widespread immune response. Moreover, PD-associated genes and risk factors have been increasingly recognized as essential regulators of immune functions. This review summarizes the current understanding of adaptive immunity in PD and explores emerging immunomodulatory strategies that may inform future therapeutic development.<\/jats:p>","DOI":"10.1515\/nipt-2025-0008","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:37:17Z","timestamp":1750387037000},"page":"273-284","source":"Crossref","is-referenced-by-count":7,"title":["Adaptive immunity in the pathogenesis and treatments of Parkinson\u2019s disease"],"prefix":"10.1515","volume":"4","author":[{"given":"Xiaoqing","family":"Du","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Akter","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina B.","family":"Oludipe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Sil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-6149","authenticated-orcid":false,"given":"R. Lee","family":"Mosley","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, College of Medicine , 12284 University of Nebraska Medical Center , Omaha , NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025072913052728144_j_nipt-2025-0008_ref_001","doi-asserted-by":"crossref","unstructured":"Tansey, MG, Wallings, RL, Houser, MC, Herrick, MK, Keating, CE, Joers, V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 2022;22:657\u201373. https:\/\/doi.org\/10.1038\/s41577-022-00684-6.","DOI":"10.1038\/s41577-022-00684-6"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_002","doi-asserted-by":"crossref","unstructured":"Herrick, MK, Tansey, MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson\u2019s disease? NPJ Parkinson\u2019s Dis 2021;7:26. https:\/\/doi.org\/10.1038\/s41531-021-00170-1.","DOI":"10.1038\/s41531-021-00170-1"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_003","doi-asserted-by":"crossref","unstructured":"Schonhoff, AM, Williams, GP, Wallen, ZD, Standaert, DG, Harms, AS. Innate and adaptive immune responses in Parkinson\u2019s disease. Prog Brain Res 2020;252:169\u2013216. https:\/\/doi.org\/10.1016\/bs.pbr.2019.10.006.","DOI":"10.1016\/bs.pbr.2019.10.006"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_004","doi-asserted-by":"crossref","unstructured":"Galiano-Landeira, J, Torra, A, Vila, M, Bove, J. CD8\u202fT cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 2020;143:3717\u201333. https:\/\/doi.org\/10.1093\/brain\/awaa269.","DOI":"10.1093\/brain\/awaa269"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_005","doi-asserted-by":"crossref","unstructured":"Sulzer, D, Alcalay, RN, Garretti, F, Cote, L, Kanter, E, Agin-Liebes, J, et al.. T cells from patients with Parkinson\u2019s disease recognize alpha-synuclein peptides. Nature 2017;546:656\u201361. https:\/\/doi.org\/10.1038\/nature22815.","DOI":"10.1038\/nature22815"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_006","doi-asserted-by":"crossref","unstructured":"Lauritsen, J, Romero-Ramos, M. The systemic immune response in Parkinson\u2019s disease: focus on the peripheral immune component. Trends Neurosci 2023;46:863\u201378. https:\/\/doi.org\/10.1016\/j.tins.2023.07.005.","DOI":"10.1016\/j.tins.2023.07.005"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_007","doi-asserted-by":"crossref","unstructured":"Bisi, N, Feni, L, Peqini, K, Perez-Pena, H, Ongeri, S, Pieraccini, S, et al.. Alpha-synuclein: an all-inclusive trip around its structure, influencing factors and applied techniques. Front Chem 2021;9:666585. https:\/\/doi.org\/10.3389\/fchem.2021.666585.","DOI":"10.3389\/fchem.2021.666585"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_008","unstructured":"Kouli, A, Torsney, KM, Kuan, WL. Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker, TB, Greenland, JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane, AU; 2018."},{"key":"2025072913052728144_j_nipt-2025-0008_ref_009","doi-asserted-by":"crossref","unstructured":"Wong, YC, Krainc, D. Alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 2017;23:1\u201313. https:\/\/doi.org\/10.1038\/nm.4269.","DOI":"10.1038\/nm.4269"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_010","doi-asserted-by":"crossref","unstructured":"Calabresi, P, Mechelli, A, Natale, G, Volpicelli-Daley, L, Di Lazzaro, G, Ghiglieri, V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 2023;14:176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9.","DOI":"10.1038\/s41419-023-05672-9"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_011","doi-asserted-by":"crossref","unstructured":"Estaun-Panzano, J, Arotcarena, ML, Bezard, E. Monitoring alpha-synuclein aggregation. Neurobiol Dis 2023;176:105966. https:\/\/doi.org\/10.1016\/j.nbd.2022.105966.","DOI":"10.1016\/j.nbd.2022.105966"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_012","doi-asserted-by":"crossref","unstructured":"Bengoa-Vergniory, N, Roberts, RF, Wade-Martins, R, Alegre-Abarrategui, J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol 2017;134:819\u201338. https:\/\/doi.org\/10.1007\/s00401-017-1755-1.","DOI":"10.1007\/s00401-017-1755-1"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_013","doi-asserted-by":"crossref","unstructured":"Mehra, MR, Uriel, N, Naka, Y, Cleveland, JCJr., Yuzefpolskaya, M, Salerno, CT, et al.. A fully magnetically levitated left ventricular assist device \u2013 final report. N Engl J Med 2019;380:1618\u201327. https:\/\/doi.org\/10.1056\/nejmoa1900486.","DOI":"10.1056\/NEJMoa1900486"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_014","doi-asserted-by":"crossref","unstructured":"Schmid, AB, Nee, RJ, Coppieters, MW. Reappraising entrapment neuropathies \u2013 mechanisms, diagnosis and management. Man Ther 2013;18:449\u201357. https:\/\/doi.org\/10.1016\/j.math.2013.07.006.","DOI":"10.1016\/j.math.2013.07.006"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_015","doi-asserted-by":"crossref","unstructured":"Samuel, BS, Rowedder, H, Braendle, C, Felix, MA, Ruvkun, G. Caenorhabditis elegans responses to bacteria from its natural habitats. Proc Natl Acad Sci U S A 2016;113:E3941\u20139. https:\/\/doi.org\/10.1073\/pnas.1607183113.","DOI":"10.1073\/pnas.1607183113"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_016","doi-asserted-by":"crossref","unstructured":"Srinivasan, E, Chandrasekhar, G, Chandrasekar, P, Anbarasu, K, Vickram, AS, Karunakaran, R, et al.. Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med 2021;8:736978. https:\/\/doi.org\/10.3389\/fmed.2021.736978.","DOI":"10.3389\/fmed.2021.736978"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_017","doi-asserted-by":"crossref","unstructured":"Steiner, JA, Angot, E, Brundin, P. A deadly spread: cellular mechanisms of alpha-synuclein transfer. Cell Death Differ 2011;18:1425\u201333. https:\/\/doi.org\/10.1038\/cdd.2011.53.","DOI":"10.1038\/cdd.2011.53"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_018","doi-asserted-by":"crossref","unstructured":"Negi, S, Khurana, N, Duggal, N. The misfolding mystery: alpha-synuclein and the pathogenesis of Parkinson\u2019s disease. Neurochem Int 2024;177:105760. https:\/\/doi.org\/10.1016\/j.neuint.2024.105760.","DOI":"10.1016\/j.neuint.2024.105760"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_019","doi-asserted-by":"crossref","unstructured":"Choi, EH, Kim, MH, Park, SJ. Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. Int J Mol Sci 2024;25:7952. https:\/\/doi.org\/10.3390\/ijms25147952.","DOI":"10.3390\/ijms25147952"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_020","doi-asserted-by":"crossref","unstructured":"Jishi, A, Hu, D, Shang, Y, Wang, R, Gunzler, SA, Qi, X. BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson\u2019s disease. Acta Neuropathol Commun 2024;12:198. https:\/\/doi.org\/10.1186\/s40478-024-01915-8.","DOI":"10.1186\/s40478-024-01915-8"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_021","doi-asserted-by":"crossref","unstructured":"Lin, MM, Liu, N, Qin, ZH, Wang, Y. Mitochondrial-derived damage-associated molecular patterns amplify neuroinflammation in neurodegenerative diseases. Acta Pharmacol Sin 2022;43:2439\u201347. https:\/\/doi.org\/10.1038\/s41401-022-00879-6.","DOI":"10.1038\/s41401-022-00879-6"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_022","doi-asserted-by":"crossref","unstructured":"Chen, C, Hertz, E, Chen, Y, Sidransky, E. Targeting protein clearance pathways in GBA1-associated Parkinson disease. Expert Opin Ther Targets 2022;26:1031\u20135. https:\/\/doi.org\/10.1080\/14728222.2022.2166828.","DOI":"10.1080\/14728222.2022.2166828"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_023","doi-asserted-by":"crossref","unstructured":"Zhao, L, Zhao, J, Zhong, K, Tong, A, Jia, D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduction Targeted Ther 2022;7:113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4.","DOI":"10.1038\/s41392-022-00966-4"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_024","doi-asserted-by":"crossref","unstructured":"Fleming, A, Bourdenx, M, Fujimaki, M, Karabiyik, C, Krause, GJ, Lopez, A, et al.. The different autophagy degradation pathways and neurodegeneration. Neuron 2022;110:935\u201366. https:\/\/doi.org\/10.1016\/j.neuron.2022.01.017.","DOI":"10.1016\/j.neuron.2022.01.017"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_025","doi-asserted-by":"crossref","unstructured":"Nuytemans, K, Theuns, J, Cruts, M, Van Broeckhoven, C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010;31:763\u201380. https:\/\/doi.org\/10.1002\/humu.21277.","DOI":"10.1002\/humu.21277"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_026","doi-asserted-by":"crossref","unstructured":"Selvaraj, S, Piramanayagam, S. Impact of gene mutation in the development of Parkinson\u2019s disease. Genes Dis 2019;6:120\u20138. https:\/\/doi.org\/10.1016\/j.gendis.2019.01.004.","DOI":"10.1016\/j.gendis.2019.01.004"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_027","doi-asserted-by":"crossref","unstructured":"Al-Azzawi, ZAM, Arfaie, S, Gan-Or, Z. GBA1 and the immune system: a potential role in Parkinson\u2019s disease? J Parkinsons Dis 2022;12:S53\u201364. https:\/\/doi.org\/10.3233\/jpd-223423.","DOI":"10.3233\/JPD-223423"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_028","doi-asserted-by":"crossref","unstructured":"Smith, L, Schapira, AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells 2022;11:1261. https:\/\/doi.org\/10.3390\/cells11081261.","DOI":"10.3390\/cells11081261"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_029","doi-asserted-by":"crossref","unstructured":"Huh, YE, Usnich, T, Scherzer, CR, Klein, C, Chung, SJ. GBA1 variants and Parkinson\u2019s disease: paving the way for targeted therapy. J Mov Disord 2023;16:261\u201378. https:\/\/doi.org\/10.14802\/jmd.23023.","DOI":"10.14802\/jmd.23023"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_030","doi-asserted-by":"crossref","unstructured":"Blauwendraat, C, Reed, X, Krohn, L, Heilbron, K, Bandres-Ciga, S, Tan, M, et al.. Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia. Brain 2020;143:234\u201348. https:\/\/doi.org\/10.1093\/brain\/awz350.","DOI":"10.1093\/brain\/awz350"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_031","doi-asserted-by":"crossref","unstructured":"Goldman, SM, Marek, K, Ottman, R, Meng, C, Comyns, K, Chan, P, et al.. Concordance for Parkinson\u2019s disease in twins: a 20-year update. Ann Neurol 2019;85:600\u20135. https:\/\/doi.org\/10.1002\/ana.25441.","DOI":"10.1002\/ana.25441"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_032","doi-asserted-by":"crossref","unstructured":"Nalls, MA, Blauwendraat, C, Vallerga, CL, Heilbron, K, Bandres-Ciga, S, Chang, D, et al.. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091\u2013102. https:\/\/doi.org\/10.1016\/s1474-4422(19)30320-5.","DOI":"10.1016\/S1474-4422(19)30320-5"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_033","doi-asserted-by":"crossref","unstructured":"Helley, MP, Pinnell, J, Sportelli, C, Tieu, K. Mitochondria: a common target for genetic mutations and environmental toxicants in Parkinson\u2019s disease. Front Genet 2017;8:177. https:\/\/doi.org\/10.3389\/fgene.2017.00177.","DOI":"10.3389\/fgene.2017.00177"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_034","doi-asserted-by":"crossref","unstructured":"Lu, J, Wu, M, Yue, Z. Autophagy and Parkinson\u2019s disease. Adv Exp Med Biol 2020;1207:21\u201351. https:\/\/doi.org\/10.1007\/978-981-15-4272-5_2.","DOI":"10.1007\/978-981-15-4272-5_2"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_035","doi-asserted-by":"crossref","unstructured":"Bailey, HM, Cookson, MR. How Parkinson\u2019s disease-linked LRRK2 mutations affect different CNS cell types. J Parkinsons Dis 2024;14:1331\u201352. https:\/\/doi.org\/10.3233\/jpd-230432.","DOI":"10.3233\/JPD-230432"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_036","doi-asserted-by":"crossref","unstructured":"Wallings, RL, Tansey, MG. LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Trans 2019;47:1581\u201395. https:\/\/doi.org\/10.1042\/bst20180463.","DOI":"10.1042\/BST20180463"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_037","doi-asserted-by":"crossref","unstructured":"Kam, TI, Hinkle, JT, Dawson, TM, Dawson, VL. Microglia and astrocyte dysfunction in Parkinson\u2019s disease. Neurobiol Dis 2020;144:105028. https:\/\/doi.org\/10.1016\/j.nbd.2020.105028.","DOI":"10.1016\/j.nbd.2020.105028"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_038","doi-asserted-by":"crossref","unstructured":"Ryter, SW, Choi, AM. Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl Res 2016;167:7\u201334. https:\/\/doi.org\/10.1016\/j.trsl.2015.06.011.","DOI":"10.1016\/j.trsl.2015.06.011"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_039","doi-asserted-by":"crossref","unstructured":"Gendelman, HE, Zhang, Y, Santamaria, P, Olson, KE, Schutt, CR, Bhatti, D, et al.. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. NPJ Parkinson\u2019s Dis 2017;3:10. https:\/\/doi.org\/10.1038\/s41531-017-0013-5.","DOI":"10.1038\/s41531-017-0013-5"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_040","doi-asserted-by":"crossref","unstructured":"Parnetti, L, Gaetani, L, Eusebi, P, Paciotti, S, Hansson, O, El-Agnaf, O, et al.. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 2019;18:573\u201386. https:\/\/doi.org\/10.1016\/s1474-4422(19)30024-9.","DOI":"10.1016\/S1474-4422(19)30024-9"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_041","doi-asserted-by":"crossref","unstructured":"Sargent, D, Moore, DJ. Mechanisms of VPS35-mediated neurodegeneration in Parkinson\u2019s disease. Int Rev Mov Disord 2021;2:221\u201344. https:\/\/doi.org\/10.1016\/bs.irmvd.2021.08.005.","DOI":"10.1016\/bs.irmvd.2021.08.005"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_042","doi-asserted-by":"crossref","unstructured":"Williams, ET, Chen, X, Otero, PA, Moore, DJ. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease. Neurobiol Dis 2022;170:105768. https:\/\/doi.org\/10.1016\/j.nbd.2022.105768.","DOI":"10.1016\/j.nbd.2022.105768"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_043","doi-asserted-by":"crossref","unstructured":"Lind-Holm Mogensen, F, Scafidi, A, Poli, A, Michelucci, A. PARK7\/DJ-1 in microglia: implications in Parkinson\u2019s disease and relevance as a therapeutic target. J Neuroinflammation 2023;20:95. https:\/\/doi.org\/10.1186\/s12974-023-02776-z.","DOI":"10.1186\/s12974-023-02776-z"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_044","doi-asserted-by":"crossref","unstructured":"Sun, S, Hou, H, Ma, G, Ma, Q, Li, N, Zhang, L, et al.. The interaction between E3 ubiquitin ligase Parkin and mitophagy receptor PHB2 links inner mitochondrial membrane ubiquitination to efficient mitophagy. J Biol Chem 2022;298:102704. https:\/\/doi.org\/10.1016\/j.jbc.2022.102704.","DOI":"10.1016\/j.jbc.2022.102704"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_045","doi-asserted-by":"crossref","unstructured":"Aly, KA, Moutaoufik, MT, Zilocchi, M, Phanse, S, Babu, M. Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)\u2606. Curr Opin Chem Biol 2022;71:102211. https:\/\/doi.org\/10.1016\/j.cbpa.2022.102211.","DOI":"10.1016\/j.cbpa.2022.102211"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_046","doi-asserted-by":"crossref","unstructured":"Lewin, CDC, Leamy, M, Palmer, L. How do people conceptualize self-harm recovery and what helps in adolescence, young and middle adulthood? A qualitative meta-synthesis. J Clin Psychol 2024;80:39\u201364. https:\/\/doi.org\/10.1002\/jclp.23588.","DOI":"10.1002\/jclp.23588"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_047","doi-asserted-by":"crossref","unstructured":"Klann, EM, Dissanayake, U, Gurrala, A, Farrer, M, Shukla, AW, Ramirez-Zamora, A, et al.. The gut-brain axis and its relation to Parkinson\u2019s disease: a review. Front Aging Neurosci 2021;13:782082. https:\/\/doi.org\/10.3389\/fnagi.2021.782082.","DOI":"10.3389\/fnagi.2021.782082"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_048","doi-asserted-by":"crossref","unstructured":"Solanki, R, Karande, A, Ranganathan, P. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration. Front Neurol 2023;14:1149618. https:\/\/doi.org\/10.3389\/fneur.2023.1149618.","DOI":"10.3389\/fneur.2023.1149618"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_049","doi-asserted-by":"crossref","unstructured":"Fulling, C, Dinan, TG, Cryan, JF. Gut microbe to brain signaling: what happens in vagus. Neuron 2019;101:998\u20131002. https:\/\/doi.org\/10.1016\/j.neuron.2019.02.008.","DOI":"10.1016\/j.neuron.2019.02.008"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_050","doi-asserted-by":"crossref","unstructured":"Zhu, M, Liu, X, Ye, Y, Yan, X, Cheng, Y, Zhao, L, et al.. Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease. Front Immunol 2022;13:937555. https:\/\/doi.org\/10.3389\/fimmu.2022.937555.","DOI":"10.3389\/fimmu.2022.937555"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_051","doi-asserted-by":"crossref","unstructured":"Tan, AH, Hor, JW, Chong, CW, Lim, SY. Probiotics for Parkinson\u2019s disease: current evidence and future directions. JGH Open 2021;5:414\u20139. https:\/\/doi.org\/10.1002\/jgh3.12450.","DOI":"10.1002\/jgh3.12450"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_052","doi-asserted-by":"crossref","unstructured":"Tan, AH, Lim, SY, Lang, AE. The microbiome-gut-brain axis in Parkinson disease \u2013 from basic research to the clinic. Nat Rev Neurol 2022;18:476\u201395. https:\/\/doi.org\/10.1038\/s41582-022-00681-2.","DOI":"10.1038\/s41582-022-00681-2"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_053","doi-asserted-by":"crossref","unstructured":"Kalyan, M, Tousif, AH, Sonali, S, Vichitra, C, Sunanda, T, Praveenraj, SS, et al.. Role of endogenous lipopolysaccharides in neurological disorders. Cells 2022;11. https:\/\/doi.org\/10.3390\/cells11244038.","DOI":"10.3390\/cells11244038"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_054","doi-asserted-by":"crossref","unstructured":"Kowalski, K, Mulak, A. Brain-gut-microbiota axis in Alzheimer\u2019s disease. J Neurogastroenterol Motil 2019;25:48\u201360. https:\/\/doi.org\/10.5056\/jnm18087.","DOI":"10.5056\/jnm18087"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_055","doi-asserted-by":"crossref","unstructured":"Sochocka, M, Donskow-Lysoniewska, K, Diniz, BS, Kurpas, D, Brzozowska, E, Leszek, J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer\u2019s disease-a critical review. Mol Neurobiol 2019;56:1841\u201351. https:\/\/doi.org\/10.1007\/s12035-018-1188-4.","DOI":"10.1007\/s12035-018-1188-4"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_056","doi-asserted-by":"crossref","unstructured":"Du, L, Lei, X, Wang, J, Wang, L, Zhong, Q, Fang, X, et al.. Lipopolysaccharides derived from Gram-negative bacterial pool of human gut microbiota promote inflammation and obesity development. Int Rev Immunol 2022;41:45\u201356. https:\/\/doi.org\/10.1080\/08830185.2021.1996573.","DOI":"10.1080\/08830185.2021.1996573"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_057","doi-asserted-by":"crossref","unstructured":"Skrzypczak-Wiercioch, A, Salat, K. Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use. Molecules 2022;27. https:\/\/doi.org\/10.3390\/molecules27175481.","DOI":"10.3390\/molecules27175481"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_058","doi-asserted-by":"crossref","unstructured":"Braniste, V, Al-Asmakh, M, Kowal, C, Anuar, F, Abbaspour, A, Toth, M, et al.. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 2014;6:263ra158. https:\/\/doi.org\/10.1126\/scitranslmed.3009759.","DOI":"10.1126\/scitranslmed.3009759"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_059","doi-asserted-by":"crossref","unstructured":"Knox, EG, Aburto, MR, Clarke, G, Cryan, JF, O\u2019Driscoll, CM. The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry 2022;27:2659\u201373. https:\/\/doi.org\/10.1038\/s41380-022-01511-z.","DOI":"10.1038\/s41380-022-01511-z"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_060","doi-asserted-by":"crossref","unstructured":"Rietdijk, CD, Perez-Pardo, P, Garssen, J, van Wezel, RJ, Kraneveld, AD. Exploring braak\u2019s hypothesis of Parkinson\u2019s disease. Front Neurol 2017;8:37. https:\/\/doi.org\/10.3389\/fneur.2017.00037.","DOI":"10.3389\/fneur.2017.00037"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_061","doi-asserted-by":"crossref","unstructured":"Breit, S, Kupferberg, A, Rogler, G, Hasler, G. Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front Psychiatry 2018;9:44. https:\/\/doi.org\/10.3389\/fpsyt.2018.00044.","DOI":"10.3389\/fpsyt.2018.00044"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_062","doi-asserted-by":"crossref","unstructured":"Han, Y, Wang, B, Gao, H, He, C, Hua, R, Liang, C, et al.. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. J Inflamm Res 2022;15:6213\u201330. https:\/\/doi.org\/10.2147\/jir.s384949.","DOI":"10.2147\/JIR.S384949"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_063","doi-asserted-by":"crossref","unstructured":"Suarez, AN, Hsu, TM, Liu, CM, Noble, EE, Cortella, AM, Nakamoto, EM, et al.. Gut vagal sensory signaling regulates hippocampus function through multi-order pathways. Nat Commun 2018;9:2181. https:\/\/doi.org\/10.1038\/s41467-018-04639-1.","DOI":"10.1038\/s41467-018-04639-1"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_064","doi-asserted-by":"crossref","unstructured":"Chantra, S, Chaitanuwong, P, Seresirikachorm, K, Brinks, M, Serirat, O, Chamberlain, W, et al.. Ocular surface erosion after suspected exposure to evaporated COVID-19 vaccine. Case Rep Ophthalmol 2021;12:944\u201351. https:\/\/doi.org\/10.1159\/000520500.","DOI":"10.1159\/000520500"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_065","doi-asserted-by":"crossref","unstructured":"Roodveldt, C, Bernardino, L, Oztop-Cakmak, O, Dragic, M, Fladmark, KE, Ertan, S, et al.. The immune system in Parkinson\u2019s disease: what we know so far. Brain 2024;147:3306\u201324. https:\/\/doi.org\/10.1093\/brain\/awae177.","DOI":"10.1093\/brain\/awae177"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_066","doi-asserted-by":"crossref","unstructured":"Marchetti, L, Engelhardt, B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc Biol 2020;2:H1\u201318. https:\/\/doi.org\/10.1530\/vb-19-0033.","DOI":"10.1530\/VB-19-0033"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_067","doi-asserted-by":"crossref","unstructured":"Karikari, AA, McFleder, RL, Ribechini, E, Blum, R, Bruttel, V, Knorr, S, et al.. Neurodegeneration by alpha-synuclein-specific T cells in AAV-A53T-alpha-synuclein Parkinson\u2019s disease mice. Brain Behav Immun 2022;101:194\u2013210. https:\/\/doi.org\/10.1016\/j.bbi.2022.01.007.","DOI":"10.1016\/j.bbi.2022.01.007"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_068","doi-asserted-by":"crossref","unstructured":"Saunders, JA, Estes, KA, Kosloski, LM, Allen, HE, Dempsey, KM, Torres-Russotto, DR, et al.. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J Neuroimmune Pharmacol 2012;7:927\u201338. https:\/\/doi.org\/10.1007\/s11481-012-9402-z.","DOI":"10.1007\/s11481-012-9402-z"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_069","doi-asserted-by":"crossref","unstructured":"Pang, X, He, X, Qiu, Z, Zhang, H, Xie, R, Liu, Z, et al.. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduction Targeted Ther 2023;8:1. https:\/\/doi.org\/10.1038\/s41392-022-01259-6.","DOI":"10.1038\/s41392-022-01259-6"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_070","doi-asserted-by":"crossref","unstructured":"Machhi, J, Kevadiya, BD, Muhammad, IK, Herskovitz, J, Olson, KE, Mosley, RL, et al.. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener 2020;15:32. https:\/\/doi.org\/10.1186\/s13024-020-00375-7.","DOI":"10.1186\/s13024-020-00375-7"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_071","doi-asserted-by":"crossref","unstructured":"Korn, T, Kallies, A. T cell responses in the central nervous system. Nat Rev Immunol 2017;17:179\u201394. https:\/\/doi.org\/10.1038\/nri.2016.144.","DOI":"10.1038\/nri.2016.144"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_072","doi-asserted-by":"crossref","unstructured":"Weiss, F, Labrador-Garrido, A, Dzamko, N, Halliday, G. Immune responses in the Parkinson\u2019s disease brain. Neurobiol Dis 2022;168:105700. https:\/\/doi.org\/10.1016\/j.nbd.2022.105700.","DOI":"10.1016\/j.nbd.2022.105700"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_073","doi-asserted-by":"crossref","unstructured":"Rickenbach, C, Gericke, C. Specificity of adaptive immune responses in central nervous system health, aging and diseases. Front Neurosci 2021;15:806260. https:\/\/doi.org\/10.3389\/fnins.2021.806260.","DOI":"10.3389\/fnins.2021.806260"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_074","doi-asserted-by":"crossref","unstructured":"Saleh, M, Markovic, M, Olson, KE, Gendelman, HE, Mosley, RL. Therapeutic strategies for immune transformation in Parkinson\u2019s disease. J Parkinsons Dis 2022;12:S201\u20132. https:\/\/doi.org\/10.3233\/jpd-223278.","DOI":"10.3233\/JPD-223278"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_075","doi-asserted-by":"crossref","unstructured":"Pacheco, R. T-cell based immunotherapies for Parkinsons disease. Explor Neuroprot Ther 2021;1:72\u201385. https:\/\/doi.org\/10.37349\/ent.2021.00007.","DOI":"10.37349\/ent.2021.00007"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_076","doi-asserted-by":"crossref","unstructured":"Jiang, Z, Huang, H, Chen, Y, Xie, H, Lu, Y, Ge, Y, et al.. The role of the immune system in Parkinson\u2019s disease pathogenesis: a focus on Th17 cells \u2013 a systematic review and meta-analysis. J Neuroimmunol 2025;398:578484. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578484.","DOI":"10.1016\/j.jneuroim.2024.578484"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_077","doi-asserted-by":"crossref","unstructured":"Sun, M, You, H, Hu, X, Luo, Y, Zhang, Z, Song, Y, et al.. Microglia-astrocyte interaction in neural development and neural pathogenesis. Cells 2023;12. https:\/\/doi.org\/10.3390\/cells12151942.","DOI":"10.3390\/cells12151942"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_078","doi-asserted-by":"crossref","unstructured":"Campos-Acuna, J, Elgueta, D, Pacheco, R. T-cell-driven inflammation as a mediator of the gut-brain axis involved in Parkinson\u2019s disease. Front Immunol 2019;10:239. https:\/\/doi.org\/10.3389\/fimmu.2019.00239.","DOI":"10.3389\/fimmu.2019.00239"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_079","doi-asserted-by":"crossref","unstructured":"Schwab, AD, Thurston, MJ, Machhi, J, Olson, KE, Namminga, KL, Gendelman, HE, et al.. Immunotherapy for Parkinson\u2019s disease. Neurobiol Dis 2020;137:104760. https:\/\/doi.org\/10.1016\/j.nbd.2020.104760.","DOI":"10.1016\/j.nbd.2020.104760"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_080","doi-asserted-by":"crossref","unstructured":"Olson, KE, Abdelmoaty, MM, Namminga, KL, Lu, Y, Obaro, H, Santamaria, P, et al.. An open-label multiyear study of sargramostim-treated Parkinson\u2019s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Transl Neurodegener 2023;12:26. https:\/\/doi.org\/10.1186\/s40035-023-00361-1.","DOI":"10.1186\/s40035-023-00361-1"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_081","doi-asserted-by":"crossref","unstructured":"Rauschenberger, L, Behnke, J, Grotemeyer, A, Knorr, S, Volkmann, J, Ip, CW. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P\/A53T double-mutated alpha-synuclein mouse model of Parkinson\u2019s disease. Neurobiol Dis 2022;171:105798. https:\/\/doi.org\/10.1016\/j.nbd.2022.105798.","DOI":"10.1016\/j.nbd.2022.105798"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_082","doi-asserted-by":"crossref","unstructured":"Mockus, TE, Ren, HM, Shwetank, Lukacher, AE. To go or stay: the development, benefit, and detriment of tissue-resident memory CD8\u202fT cells during central nervous system viral infections. Viruses 2019;11. https:\/\/doi.org\/10.3390\/v11090842.","DOI":"10.3390\/v11090842"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_083","doi-asserted-by":"crossref","unstructured":"Zhang, Z, Lv, M, Zhou, X, Cui, Y. Roles of peripheral immune cells in the recovery of neurological function after ischemic stroke. Front Cell Neurosci 2022;16:1013905. https:\/\/doi.org\/10.3389\/fncel.2022.1013905.","DOI":"10.3389\/fncel.2022.1013905"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_084","doi-asserted-by":"crossref","unstructured":"Bersano, A, Engele, J, Schafer, MKE. Neuroinflammation and brain disease. BMC Neurol 2023;23:227. https:\/\/doi.org\/10.1186\/s12883-023-03252-0.","DOI":"10.1186\/s12883-023-03252-0"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_085","doi-asserted-by":"crossref","unstructured":"Chen, Z, Islam, M, Ford, KP, Zhao, G, Chen, SY, Wang, Y, et al.. Microglia and infiltrating T-cells adopt long-term, age-specific, transcriptional changes after traumatic brain injury in mice. Shock 2023;59:267\u201376. https:\/\/doi.org\/10.1097\/shk.0000000000002027.","DOI":"10.1097\/SHK.0000000000002027"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_086","doi-asserted-by":"crossref","unstructured":"Zhang, Z, Duan, Z, Cui, Y. CD8(+) T cells in brain injury and neurodegeneration. Front Cell Neurosci 2023;17:1281763. https:\/\/doi.org\/10.3389\/fncel.2023.1281763.","DOI":"10.3389\/fncel.2023.1281763"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_087","doi-asserted-by":"crossref","unstructured":"Yoshimura, A, Ohyagi, M, Ito, M. T cells in the brain inflammation. Adv Immunol 2023;157:29\u201358. https:\/\/doi.org\/10.1016\/bs.ai.2022.10.001.","DOI":"10.1016\/bs.ai.2022.10.001"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_088","doi-asserted-by":"crossref","unstructured":"Weng, NP. Numbers and odds: TCR repertoire size and its age changes impacting on T cell functions. Semin Immunol 2023;69:101810. https:\/\/doi.org\/10.1016\/j.smim.2023.101810.","DOI":"10.1016\/j.smim.2023.101810"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_089","doi-asserted-by":"crossref","unstructured":"Terrabuio, E, Zenaro, E, Constantin, G. The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders. Front Immunol 2023;14:1233870. https:\/\/doi.org\/10.3389\/fimmu.2023.1233870.","DOI":"10.3389\/fimmu.2023.1233870"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_090","doi-asserted-by":"crossref","unstructured":"Olson, KE, Gendelman, HE. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson\u2019s disease. Curr Opin Pharmacol 2016;26:87\u201395. https:\/\/doi.org\/10.1016\/j.coph.2015.10.006.","DOI":"10.1016\/j.coph.2015.10.006"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_091","doi-asserted-by":"crossref","unstructured":"Reynolds, AD, Stone, DK, Mosley, RL, Gendelman, HE. Nitrated alpha-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009;182:4137\u201349. https:\/\/doi.org\/10.4049\/jimmunol.0803982.","DOI":"10.4049\/jimmunol.0803982"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_092","doi-asserted-by":"crossref","unstructured":"Reynolds, AD, Banerjee, R, Liu, J, Gendelman, HE, Mosley, RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson\u2019s disease. J Leukoc Biol 2007;82:1083\u201394. https:\/\/doi.org\/10.1189\/jlb.0507296.","DOI":"10.1189\/jlb.0507296"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_093","doi-asserted-by":"crossref","unstructured":"Reynolds, AD, Stone, DK, Hutter, JA, Benner, EJ, Mosley, RL, Gendelman, HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson\u2019s disease. J Immunol 2010;184:2261\u201371. https:\/\/doi.org\/10.4049\/jimmunol.0901852.","DOI":"10.4049\/jimmunol.0901852"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_094","doi-asserted-by":"crossref","unstructured":"Schutt, CR, Gendelman, HE, Mosley, RL. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson\u2019s disease. Mol Neurodegener 2018;13:26. https:\/\/doi.org\/10.1186\/s13024-018-0255-7.","DOI":"10.1186\/s13024-018-0255-7"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_095","doi-asserted-by":"crossref","unstructured":"Olson, KE, Namminga, KL, Lu, Y, Schwab, AD, Thurston, MJ, Abdelmoaty, MM, et al.. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson\u2019s disease. EBioMedicine 2021;67:103380. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103380.","DOI":"10.1016\/j.ebiom.2021.103380"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_096","doi-asserted-by":"crossref","unstructured":"Holden, SK, Finseth, T, Sillau, SH, Berman, BD. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s progression markers initiative cohort. Mov Disord Clin Pract 2018;5:47\u201353. https:\/\/doi.org\/10.1002\/mdc3.12553.","DOI":"10.1002\/mdc3.12553"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_097","doi-asserted-by":"crossref","unstructured":"Kohm, AP, Turley, DM, Miller, SD. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease. Int Rev Immunol 2005;24:361\u201392. https:\/\/doi.org\/10.1080\/08830180500371207.","DOI":"10.1080\/08830180500371207"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_098","doi-asserted-by":"crossref","unstructured":"Kuhn, C, Weiner, HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy 2016;8:889\u2013906. https:\/\/doi.org\/10.2217\/imt-2016-0049.","DOI":"10.2217\/imt-2016-0049"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_099","doi-asserted-by":"crossref","unstructured":"Olson, KE, Kosloski-Bilek, LM, Anderson, KM, Diggs, BJ, Clark, BE, Gledhill, JMJr., et al.. Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice. J Neurosci 2015;35:16463\u201378. https:\/\/doi.org\/10.1523\/jneurosci.2131-15.2015.","DOI":"10.1523\/JNEUROSCI.2131-15.2015"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_100","doi-asserted-by":"crossref","unstructured":"Mosley, RL, Lu, Y, Olson, KE, Machhi, J, Yan, W, Namminga, KL, et al.. A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson\u2019s disease. Front Cell Neurosci 2019;13:421. https:\/\/doi.org\/10.3389\/fncel.2019.00421.","DOI":"10.3389\/fncel.2019.00421"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_101","doi-asserted-by":"crossref","unstructured":"Markovic, M, Yeapuri, P, Namminga, KL, Lu, Y, Saleh, M, Olson, KE, et al.. Interleukin-2 expands neuroprotective regulatory T cells in Parkinson\u2019s disease. Neuroimmune Pharmacol Ther 2022;1:43\u201350. https:\/\/doi.org\/10.1515\/nipt-2022-0001.","DOI":"10.1515\/nipt-2022-0001"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_102","doi-asserted-by":"crossref","unstructured":"Liston, A, Pasciuto, E, Fitzgerald, DC, Yshii, L. Brain regulatory T cells. Nat Rev Immunol 2024;24:326\u201337. https:\/\/doi.org\/10.1038\/s41577-023-00960-z.","DOI":"10.1038\/s41577-023-00960-z"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_103","doi-asserted-by":"crossref","unstructured":"Ciurkiewicz, M, Herder, V, Beineke, A. Beneficial and detrimental effects of regulatory T cells in neurotropic virus infections. Int J Mol Sci 2020;21. https:\/\/doi.org\/10.3390\/ijms21051705.","DOI":"10.3390\/ijms21051705"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_104","doi-asserted-by":"crossref","unstructured":"Harkins, AL, Kopec, AL, Keeler, AM. Regulatory T cell therapeutics for neuroinflammatory disorders. Crit Rev Immunol 2022;42:1\u201327. https:\/\/doi.org\/10.1615\/critrevimmunol.2022045080.","DOI":"10.1615\/CritRevImmunol.2022045080"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_105","doi-asserted-by":"crossref","unstructured":"Jafarzadeh, A, Sheikhi, A, Jafarzadeh, Z, Nemati, M. Differential roles of regulatory T cells in Alzheimer\u2019s disease. Cell Immunol 2023;393\u2013394:104778. https:\/\/doi.org\/10.1016\/j.cellimm.2023.104778.","DOI":"10.1016\/j.cellimm.2023.104778"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_106","doi-asserted-by":"crossref","unstructured":"Jain, RW, Yong, VW. B cells in central nervous system disease: diversity, locations and pathophysiology. Nat Rev Immunol 2022;22:513\u201324. https:\/\/doi.org\/10.1038\/s41577-021-00652-6.","DOI":"10.1038\/s41577-021-00652-6"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_107","doi-asserted-by":"crossref","unstructured":"Sabatino, JJJr., Probstel, AK, Zamvil, SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci 2019;20:728\u201345. https:\/\/doi.org\/10.1038\/s41583-019-0233-2.","DOI":"10.1038\/s41583-019-0233-2"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_108","doi-asserted-by":"crossref","unstructured":"Scott, KM. B lymphocytes in Parkinson\u2019s disease. J Parkinsons Dis 2022;12:S75\u201381. https:\/\/doi.org\/10.3233\/jpd-223418.","DOI":"10.3233\/JPD-223418"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_109","doi-asserted-by":"crossref","unstructured":"Wang, P, Luo, M, Zhou, W, Jin, X, Xu, Z, Yan, S, et al.. Global characterization of peripheral B cells in Parkinson\u2019s disease by single-cell RNA and BCR sequencing. Front Immunol 2022;13:814239. https:\/\/doi.org\/10.3389\/fimmu.2022.814239.","DOI":"10.3389\/fimmu.2022.814239"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_110","doi-asserted-by":"crossref","unstructured":"Kubo, M, Nagashima, R, Ohta, E, Maekawa, T, Isobe, Y, Kurihara, M, et al.. Leucine-rich repeat kinase 2 is a regulator of B cell function, affecting homeostasis, BCR signaling, IgA production, and TI antigen responses. J Neuroimmunol 2016;292:1\u20138. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.005.","DOI":"10.1016\/j.jneuroim.2016.01.005"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_111","doi-asserted-by":"crossref","unstructured":"Horvath, I, Iashchishyn, IA, Forsgren, L, Morozova-Roche, LA. Immunochemical detection of alpha-synuclein autoantibodies in Parkinson\u2019s disease: correlation between plasma and cerebrospinal fluid levels. ACS Chem Neurosci 2017;8:1170\u20136. https:\/\/doi.org\/10.1021\/acschemneuro.7b00063.","DOI":"10.1021\/acschemneuro.7b00063"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_112","doi-asserted-by":"crossref","unstructured":"Akhtar, RS, Licata, JP, Luk, KC, Shaw, LM, Trojanowski, JQ, Lee, VM. Measurements of auto-antibodies to alpha-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease. J Neurochem 2018;145:489\u2013503. https:\/\/doi.org\/10.1111\/jnc.14330.","DOI":"10.1111\/jnc.14330"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_113","doi-asserted-by":"crossref","unstructured":"Benner, EJ, Banerjee, R, Reynolds, AD, Sherman, S, Pisarev, VM, Tsiperson, V, et al.. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008;3:e1376. https:\/\/doi.org\/10.1371\/journal.pone.0001376.","DOI":"10.1371\/journal.pone.0001376"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_114","doi-asserted-by":"crossref","unstructured":"Chen, S, Le, WD, Xie, WJ, Alexianu, ME, Engelhardt, JI, Siklos, L, et al.. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998;55:1075\u201380. https:\/\/doi.org\/10.1001\/archneur.55.8.1075.","DOI":"10.1001\/archneur.55.8.1075"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_115","doi-asserted-by":"crossref","unstructured":"Elkouzi, A, Vedam-Mai, V, Eisinger, RS, Okun, MS. Emerging therapies in Parkinson disease \u2013 repurposed drugs and new approaches. Nat Rev Neurol 2019;15:204\u201323. https:\/\/doi.org\/10.1038\/s41582-019-0155-7.","DOI":"10.1038\/s41582-019-0155-7"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_116","doi-asserted-by":"crossref","unstructured":"Zella, SMA, Metzdorf, J, Ciftci, E, Ostendorf, F, Muhlack, S, Gold, R, et al.. Emerging immunotherapies for Parkinson disease. Neurol Ther 2019;8:29\u201344. https:\/\/doi.org\/10.1007\/s40120-018-0122-z.","DOI":"10.1007\/s40120-018-0122-z"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_117","doi-asserted-by":"crossref","unstructured":"Kalia, LV, Kalia, SK, Lang, AE. Disease-modifying strategies for Parkinson\u2019s disease. Mov Disord 2015;30:1442\u201350. https:\/\/doi.org\/10.1002\/mds.26354.","DOI":"10.1002\/mds.26354"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_118","doi-asserted-by":"crossref","unstructured":"Chatterjee, D, Kordower, JH. Immunotherapy in Parkinson\u2019s disease: current status and future directions. Neurobiol Dis 2019;132:104587. https:\/\/doi.org\/10.1016\/j.nbd.2019.104587.","DOI":"10.1016\/j.nbd.2019.104587"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_119","doi-asserted-by":"crossref","unstructured":"Alfaidi, M, Barker, RA, Kuan, WL. An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. J Neurol 2024;272:21. https:\/\/doi.org\/10.1007\/s00415-024-12770-x.","DOI":"10.1007\/s00415-024-12770-x"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_120","doi-asserted-by":"crossref","unstructured":"Gill, SS, Patel, NK, Hotton, GR, O\u2019Sullivan, K, McCarter, R, Bunnage, M, et al.. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589\u201395. https:\/\/doi.org\/10.1038\/nm850.","DOI":"10.1038\/nm850"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_121","doi-asserted-by":"crossref","unstructured":"Gash, DM, Gerhardt, GA, Bradley, LH, Wagner, R, Slevin, JT. GDNF clinical trials for Parkinson\u2019s disease: a critical human dimension. Cell Tissue Res 2020;382:65\u201370. https:\/\/doi.org\/10.1007\/s00441-020-03269-8.","DOI":"10.1007\/s00441-020-03269-8"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_122","doi-asserted-by":"crossref","unstructured":"Heiss, JD, Lungu, C, Hammoud, DA, Herscovitch, P, Ehrlich, DJ, Argersinger, DP, et al.. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov Disord 2019;34:1073\u20138. https:\/\/doi.org\/10.1002\/mds.27724.","DOI":"10.1002\/mds.27724"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_123","doi-asserted-by":"crossref","unstructured":"Axelsen, TM, Woldbye, DPD. Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis 2018;8:195\u2013215. https:\/\/doi.org\/10.3233\/jpd-181331.","DOI":"10.3233\/JPD-181331"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_124","doi-asserted-by":"crossref","unstructured":"Chmielarz, P, Saarma, M. Neurotrophic factors for disease-modifying treatments of Parkinson\u2019s disease: gaps between basic science and clinical studies. Pharmacol Rep 2020;72:1195\u2013217. https:\/\/doi.org\/10.1007\/s43440-020-00120-3.","DOI":"10.1007\/s43440-020-00120-3"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_125","doi-asserted-by":"crossref","unstructured":"Kumari, S, Kamiya, A, Karnik, SS, Rohilla, S, Dubey, SK, Taliyan, R. Novel gene therapy approaches for targeting neurodegenerative disorders: focusing on delivering neurotrophic genes. Mol Neurobiol 2025;62:386\u2013411. https:\/\/doi.org\/10.1007\/s12035-024-04260-y.","DOI":"10.1007\/s12035-024-04260-y"},{"key":"2025072913052728144_j_nipt-2025-0008_ref_126","doi-asserted-by":"crossref","unstructured":"Pfeffer, LK, Fischbach, F, Heesen, C, Friese, MA. Current state and perspectives of CAR T cell therapy in central nervous system diseases. Brain 2025;148:723\u201336. https:\/\/doi.org\/10.1093\/brain\/awae362.","DOI":"10.1093\/brain\/awae362"}],"container-title":["NeuroImmune Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2025-0008\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2025-0008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:06:29Z","timestamp":1753794389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/nipt-2025-0008\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":126,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,7,30]]}},"alternative-id":["10.1515\/nipt-2025-0008"],"URL":"https:\/\/doi.org\/10.1515\/nipt-2025-0008","relation":{},"ISSN":["2750-6665"],"issn-type":[{"value":"2750-6665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}